10.94
Oruka Therapeutics Inc stock is traded at $10.94, with a volume of 225.34K.
It is up +4.59% in the last 24 hours and up +0.27% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$10.46
Open:
$10.23
24h Volume:
225.34K
Relative Volume:
0.75
Market Cap:
$409.60M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.39%
1M Performance:
+0.27%
6M Performance:
-61.04%
1Y Performance:
+0.00%
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ORKA
Oruka Therapeutics Inc
|
10.94 | 409.60M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-04-25 | Initiated | Wolfe Research | Outperform |
Oct-11-24 | Initiated | Stifel | Buy |
Oct-07-24 | Initiated | H.C. Wainwright | Buy |
Sep-17-24 | Initiated | Leerink Partners | Outperform |
Sep-16-24 | Initiated | TD Cowen | Buy |
Sep-13-24 | Initiated | Jefferies | Buy |
Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics (NASDAQ:ORKA) Earns “Outperform” Rating from Wedbush - Defense World
We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate - Yahoo Finance
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance - TipRanks
Oruka Therapeutics Says ORKA-002 Preclinical Data Support Potential Extended Dosing Intervals - Marketscreener.com
Oruka Therapeutics: Buy Rating Backed by Strong Financials and Promising Clinical Progress - TipRanks
Oruka Therapeutics Announces Preclinical Data for ORKA-002 - GlobeNewswire
Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target - Investing.com
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting - The Manila Times
Oruka Therapeutics Posts Q4 Net Loss -March 06, 2025 at 05:18 pm EST - Marketscreener.com
Oruka Therapeutics Reports 2024 Financial Results and Progress on Psoriasis Pipeline Including ORKA-001 and ORKA-002 - Nasdaq
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Can Oruka's $394M War Chest Transform Autoimmune Disease Treatment? Key Pipeline Updates - StockTitan
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in Stock - MarketBeat
Insider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of Stock - MarketBeat
Oruka Therapeutics sees $1.41 million in stock purchases by Venrock - Investing.com Australia
Oruka Therapeutics sees $1.41 million in stock purchases by Venrock Healthcare - Investing.com
Oruka Therapeutics (ORKA) to Release Earnings on Thursday - Defense World
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics to Present at Multiple March Investor Conferences - GlobeNewswire
Can This Clinical-Stage Biotech's March Conference Circuit Signal Major Developments? - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) & Alpha Teknova (NASDAQ:TKNO) Head-To-Head Contrast - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
Financial Fitness Check: Examining Oruka Therapeutics Inc (ORKA)’s Key Ratios - The Dwinnex
Oruka Therapeutics Inc (ORKA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Oruka Therapeutics (NASDAQ:ORKA) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel
Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at Wolfe Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpTime to Buy? - MarketBeat
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Wolfe Research Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wolfe Research - Defense World
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Oruka Therapeutics initiated with an Outperform at Wolfe Research - MSN
Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday - MarketBeat
Oruka Therapeutics (ORKA) Projected to Post Earnings on Thursday - Defense World
Abio Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arca Biopharma, Inc. Is Fair to Shareholders - ACCESS Newswire
Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $43.17 - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Analysts - Defense World
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):